Pfizer, Inc. vs Arcus Biosciences, Inc. — Stock Comparison

PFE
Pfizer, Inc.
$26.33
▼ 1.39%
vs
RCUS
Arcus Biosciences, Inc.
$25.68
▲ 0.71%
Q·Score Winner
Pfizer, Inc.
PFE6.5/10vs 5.7/10

Q·Score Breakdown

6.5
Neutral
Overall
5.7
Neutral
7.4
Quality
0.2
7
Health
9.2
5.6
Growth
7.7
6.7
Valuation
5.7
5.2
Sentiment
7.2
PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

RCUS

Clean balance sheet with low leverage (0.3× debt-to-equity).

currently unprofitable (-143% margin).

Analyst Consensus

HOLD
Target $29.00 (+10.2%)
27 analysts
BUY
Target $34.00 (+32.4%)
10 analysts

Fundamentals

PFE
RCUS
19.4×
Trailing P/E
9.4×
Forward P/E
-7.3×
12.4%
Profit Margin
-142.9%
75.8%
Gross Margin
-111.7%
8.9%
ROE
-63.3%
-1.2%
Revenue Growth
26.9%
Earnings Growth
0.39
Beta
0.86
Price / Book
$149.8B
Market Cap
$3.2B
$22 – $29
52-Week Range
$7 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →